Intracellular News and Research

RSS

Book provides new insight on one of the most common infectious diseases, Chlamydia

Chlamydiae are obligate intracellular bacteria that cause one of the most common sexually transmitted infectious diseases in the world. The infection disproportionately impacts women and the highest prevalence of infection is found in adolescents.

5 Jul 2013

Research shows over 50% of tumors have mutations in p53

Researchers of the Cancer Metabolism group at the Bellvitge Biomedical Research Institute (IDIBELL), Catalan Oncology Institute (ICO) and the Division of Hematology-Oncology of the University of Cincinnati, led by George Thomas, have discovered a role for ribosomal 5S RNA in the formation of a complex that regulates the stability of p53.

4 Jul 2013

Decorin protein in blood inhibits tumor progression, say researchers

Researchers from Thomas Jefferson University's Kimmel Cancer Center have discovered that decorin, a naturally occurring protein that circulates in the blood, acts as a potent inhibitor of tumor growth modulating the tumor microenvironment.

28 Jun 2013

MPIIB researchers show that Chlamydia infections can cause mutations in host DNA

Chlamydia trachomatis is a human pathogen that is the leading cause of bacterial sexually transmitted disease worldwide with more than 90 million new cases of genital infections occurring each year. About 70 percent of women infected with Chlamydia remain asymptomatic and these bacteria can establish chronic infections for months, or even years. Even when it causes no symptoms, Chlamydia can damage a woman's reproductive organs. In addition, standard antibacterial drugs are proving increasingly ineffective in complete eradication, as Chlamydia goes in to persistent mode, leading to asymptomatic chronic infection.

21 Jun 2013

EORTC starts phase 2 trial in elderly patients with HER-2 positive metastatic breast cancer

Despite the fact that the incidence of cancer is many fold higher in persons over 65 years of age, we still have an inadequate understanding on how best to treat these older cancer patients. Furthermore, even though elderly patients are occasionally included in clinical trials, those elderly patients who are eventually included are mostly 'healthy' (fit) elderly patients.

20 Jun 2013

Bioapplications of nanoparticles: an interview with Dr Catherine Berry, University of Glasgow

These particles are all classed as inorganic particles, which can all be utilised in biomedical applications. They differ in terms of their inherent material and size dependent physiochemical properties, for example, their optical and magnetic properties.

18 Jun 2013

Scientists find that mice develop age-related progressive motor symptoms of Parkinson's disease

The presence of Lewy bodies in nerve cells, formed by intracellular deposits of the protein α-synuclein, is a characteristic pathologic feature of Parkinson's Disease (PD). In the quest for an animal model of PD that mimics motor and non-motor symptoms of human PD, scientists have developed strains of mice that overexpress α-synuclein.

10 Jun 2013

seca releases medical Body Composition Analyzer

seca, the world's market leader in medical measuring and weighing, launches its medical Body Composition Analyzer, the seca mBCA 514.

From seca 4 Jun 2013

Researchers uncover role of key protein linked to development of cancers

Virginia Commonwealth University researchers studying a key molecular player called Hsp70 that is responsible for protein homeostasis have uncovered how it binds together with another molecule responsible for intracellular energy transfer to enhance its overall activity and efficiency - details that have previously not been well understood.

1 Jun 2013

GLYX-13 drug induces antidepressant results without street drug side effects

GLYX-13, a molecular cousin to ketamine, induces similar antidepressant results without the street drug side effects, reported a study funded by the National Institute of Mental Health (NIMH) that was published last month in Neuropsychopharmacology.

31 May 2013

New research reveals how endothelium maintains highly efficient barrier function

The endothelium, the cellular layer lining the body's blood vessels, is extremely resilient. Measuring just a few hundred nanometers in thickness, this super-tenuous structure routinely withstands blood flow, hydrostatic pressure, stretch and tissue compression to create a unique and highly dynamic barrier that maintains the organization necessary to partition tissues from the body's circulatory system.

17 May 2013

Novel cell sorting enhancement to MoFlo Astrios platform to be introduced by Beckman Coulter Life Sciences at CYTO 2013

Two seminars and seven poster sessions, Beckman Coulter will have a prominent role when CYTO 2013 convenes at the San Diego Convention Center May 18-22, 2013.

From Beckman Coulter Life Sciences - Flow Cytometry 16 May 2013

Mouse study shows leukemia halts accumulation of toxic proteins linked to Parkinson's disease

Researchers at Georgetown University Medical Center have used tiny doses of a leukemia drug to halt accumulation of toxic proteins linked to Parkinson's disease in the brains of mice. This finding provides the basis to plan a clinical trial in humans to study the effects.

10 May 2013

Mutations in Ggamma13 gene may contribute to certain forms of smell disorders in humans

Researchers at the Monell Center and collaborators have identified a protein that is critical to the ability of mammals to smell. Mice engineered to be lacking the Ggamma13 protein in their olfactory receptors were functionally anosmic - unable to smell.

7 May 2013

EPAC2 and diabetes: an interview with Dr. Hussain, Johns Hopkins University

EPAC stands for exchange protein activated by cyclic AMP (cAMP). cAMP is an (among many) intracellular messenger molecule. cAMP is generated when certain hormones stimulate a cell by binding to their receptor, which is at the outside surface of the cell.

3 May 2013

Student researchers get new view of the dynamics of cancer cells as they metastasize

A team of student researchers and their professors from 20 laboratories around the country have gotten a new view of cancer cells. The work could shed light on the transforming physical properties of these cells as they metastasize, said Jack R. Staunton, a Ph.D. candidate at Arizona State University in the lab of Prof. Robert Ros, and the lead author of a paper reporting on the topic.

29 Apr 2013

Cempra demonstrates solithromycin's potential against urogenital infections at ECCMID

Cempra, Inc., a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infections, today announced that it will present data at the European Congress of Clinical Microbiology and Infectious Diseases in Berlin, demonstrating solithromycin's potential to treat urogenital infections and combat challenging pathogens such as enterococci and Legionella pneumophila.

29 Apr 2013

GI nematode infections combat obesity and improve related metabolic disorders

Researchers at the University of Maryland School of Medicine, Baltimore, have shown in a mouse model that infection with nematodes (also known as roundworms) can not only combat obesity but ameliorate related metabolic disorders.

26 Apr 2013

UB researchers develop aniontransporters to trigger cancer cell apoptosis

The journal Accounts of Chemical Research, which has a profound impact on Chemistry and other related sciences, publishes on its current issue the article "Anion Transporters and Biological Systems", signed by Professor Ricardo Pérez Tomás, from the Department of Pathology and Experimental Therapy of the Faculty of Medicine at the University of Barcelona, Roberto Quesada, from the Department of Chemistry of the Sciences Faculty at the University of Burgos, and Philip A. Gale, from the University of Southampton, in the United Kingdom.

22 Apr 2013

ARMGO Pharma gets $1 million to support ARM210 preclinical work for DMD treatment

ARMGO Pharma and the Muscular Dystrophy Association today announced that $1 Million has been awarded for preclinical work in support of an Investigational New Drug application with the U.S. Food and Drug Administration for ARM210, a novel, orally available, small-molecule Rycal drug that has potential as a treatment for Duchenne muscular dystrophy.

18 Apr 2013